Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors

Social relationships are essential for mental and physical health, and maladaptive social dynamics are implicated in many psychiatric disorders. Individual psychedelic-assisted psychotherapy (IPAP) has been developed to treat various mental health problems, but it is limited to the patient–therapist dyad and relies on patients' verbal reports. Psychedelic-assisted group psychotherapy (PAGP) offers the additional possibility that patients, peers and therapists can simultaneously observe and experience interpersonal difficulties in a shared, supportive environment. The authors situate PAGP historically—noting extensive mid-20th century psycholytic work and a recent meta-analysis that identified dozens of PAGP cases involving around 700 patients between 1956 and 1995—and observe that contemporary empirical research on PAGP remains sparse despite renewed clinical interest. Ponomarenko and colleagues set out to examine how PAGP might interact with established curative mechanisms of group therapy by using Irvin Yalom’s 11 therapeutic factors as an organising framework. The paper aims to synthesise clinical reports, contemporary trial data and relevant neurobiological findings to articulate potential benefits, mechanisms and challenges of PAGP, and to propose priorities for future research and clinical implementation.

This article is a narrative, literature-based discussion rather than a systematic review. To inform each of Yalom’s 11 therapeutic factors, the study team targeted clinical trials, neurobiological research and experiential reports from practitioners. They searched Google Scholar and PubMed between October 2021 and December 2022 and supplemented database searches with selected chapters from relevant books and practitioner experience. The authors did not restrict their synthesis to a single psychotherapeutic tradition; instead, they grouped available evidence from different PAGP frameworks (traditional group therapy with added substance sessions and models where substance sessions occur in groups while psychotherapy is individual). Where trial designs, dosing regimens or outcomes were reported in the extracted literature, these findings were integrated into the factor-by-factor discussion. The paper draws on historical psycholytic literature, contemporary open-label programs (for example a Swiss limited medical use programme), small cohort studies (including a University of California cohort of psilocybin-treated gay-identified men living with HIV) and active clinical practice reports such as ketamine group programmes.

Across the literature reviewed, the authors report convergent indications that psychedelics can amplify multiple therapeutic factors central to group psychotherapy. Historical psycholytic reports and recent open programmes describe clinical and behavioural improvements when psychedelic sessions are embedded in group formats, although study designs and outcome reporting are heterogeneous. Evidence and illustrative examples: The paper summarises several empirical and programmatic sources. A mid-20th century psycholytic literature and a recent meta-analysis were cited as reporting substantial clinical improvements across diverse diagnoses, but the extraction does not allow a full accounting of study quality or uniform outcome metrics. In contemporary work, a Swiss limited medical use programme treated 18 patients with MDMA and LSD in group sessions (variable group sizes, multi‑therapist teams, sessions spaced months apart) and reported clinical changes; a University of California study used preparatory group therapy with individual psilocybin dosing (0.3–0.36 mg/kg) followed by group integration and observed clinically meaningful reductions in demoralisation that persisted at 3 months. Two small pilot trials of psilocybin-assisted group therapy for cancer-associated major depressive disorder were noted as ongoing (NCT identifiers provided in the source text). Factor-by-factor findings: Using Yalom’s framework, the authors map specific ways psychedelics may influence group curative mechanisms. Instillation of hope: psychedelic-facilitated insights and enhanced autobiographical recall can bolster belief in recovery, and observing peers’ improvements may further increase self-efficacy. Universality: psychedelics can elicit experiences of unity and ego-diminution that reduce self-focused rumination, complementing group disclosure to decrease perceived uniqueness of suffering. Altruism and prosociality: MDMA and classic psychedelics have been associated with increased sociability, empathy and cooperative behaviour, potentially enabling reciprocal helping within groups; neurochemical changes such as enhanced oxytocin and monoamine signalling are discussed as plausible mechanisms. Corrective recapitulation of the primary family group: the group can model healthier relational patterns while psychedelics may free autobiographical material for corrective processing. Development of socialising techniques and interpersonal learning: acute prosocial effects, enhanced emotional disclosure and putative neuroplasticity (dendritic and synaptic growth reported in preclinical and some clinical studies) are proposed to facilitate practising social skills and consolidating new interpersonal behaviours. Imitative behaviour is described anecdotally as occurring during PAGP and may help members explore alternative roles and behaviours. Group cohesiveness: shared psychedelic experiences and the difficulty of describing such experiences to non‑participants can foster rapid bonding; MDMA in particular is noted as a social catalyst. Catharsis: psychedelics increase affective intensity and can enable patients to tolerate and process deep emotions, but catharsis alone is not sufficient; subsequent therapeutic processing is emphasised. Existential factors: reductions in death anxiety, increased meaning and shifts in metaphysical beliefs seen in individual psychedelic work are reported to translate into group contexts, aiding existential processing and mutual support. Safety, contraindications and practical features: General exclusions common to psychedelic research (pregnancy/breastfeeding, certain cardiovascular conditions, psychotic disorders, interacting medications) are reiterated. PAGP-specific exclusions discussed include borderline personality disorder, bipolar disorder (patients or first-degree relatives), acute substance dependency and severe deficits in social skills; Swiss long-term practice reported no additional contraindications when guidelines were followed. Structural and practical considerations were detailed: PAGP typically requires clear codes of conduct, multiple therapists coordinating roles, management of variable doses and effects within a group, and balancing periods of minimal interaction during acute effects with integration later. The authors present one detailed patient vignette (a 46-year-old woman ‘‘Maria’’) showing clinical improvement after four MDMA group sessions (initial 125 mg, then 150 mg for three sessions) alongside weekly therapy; the vignette illustrates interplay of multiple therapeutic factors but is a single-case experiential report rather than controlled evidence. Limitations in the evidence base: The extraction makes clear that the literature is heterogeneous, often open-label or observational, and that direct causal links from neurobiology to clinical outcome are not established. The authors repeatedly highlight sparse contemporary randomised data and note methodological variability across historical and current reports.

Ponomarenko and colleagues interpret the assembled literature as indicating that psychedelics have the potential to enhance central curative mechanisms of group psychotherapy. They argue that psychedelics can broaden autobiographical perspective, reduce self-focus, and increase prosocial behaviour and empathy, thereby amplifying group processes such as universality, altruism, interpersonal learning and cohesion. The discussion positions these claims relative to earlier psycholytic practice and recent IPAP findings, suggesting continuity with historical observations while noting contemporary neuroscientific hypotheses—changes in default mode network connectivity, monoaminergic and oxytocinergic effects, and neuroplasticity—that could plausibly support observed psychological changes. The authors acknowledge substantial uncertainty and limitations: the contemporary evidence base for PAGP is limited to small cohorts, open-label programmes and heterogeneous historical reports; standardised psychotherapeutic methods within trials are insufficiently specified; and neurobiological findings cannot be taken as direct proof of therapeutic mechanisms. Practical challenges are emphasised as well: PAGP may demand more rigid structure and pre-defined group rules, careful patient selection to avoid harms to group cohesion, additional therapist training (including competencies such as empathetic presence, knowledge of psychedelics, ethical integrity and skills in group interventions), and careful management of challenging or ‘‘ineffable’’ experiences so they do not increase patients’ sense of isolation. The authors also discuss institutional barriers—coordination demands, legal and training constraints—and note ethical concerns around therapist self-experience with psychedelics. On the basis of these considerations, the paper calls for more empirical research: head-to-head comparisons of PAGP with IPAP and conventional group therapy, standardisation of psychotherapeutic components in trials, long-term quantitative and qualitative outcome assessments, investigation of neurobiological correlates and predictors of response, and development of internationally recognised clinical guidelines. The authors stress that adequate therapist training and careful screening are necessary to maximise benefit and minimise the risks that arise from group dynamics, challenging acute experiences, or inadequate integration.

The authors conclude that PAGP offers a conceptually promising way to combine the acute psychological effects of psychedelic substances with the interpersonal processes central to group psychotherapy. In well-guided settings, psychedelics may act as social catalysts that amplify hope, connectedness, prosocial behaviour and opportunities for corrective interpersonal learning, while also posing unique structural and training requirements. Given the limited contemporary empirical evidence, Ponomarenko and colleagues recommend further clinical research and standardisation efforts before widespread implementation, while recognising PAGP’s potential to increase accessibility and specifically target interpersonal problems.